Your browser doesn't support javascript.
loading
Insights into the modular design of kinase inhibitors and application to Abl and Axl.
Phadke, Sameer; Lopez-Barcons, Lluis; Vandecan, Nathalie; Wu, Zhifen; Johnson, Taylor K; Lachacz, Eric J; Merajver, Sofia D; Soellner, Matthew B.
Afiliação
  • Phadke S; Department of Chemistry, University of Michigan 930 N. University Ave. Ann Arbor MI 48109 USA soellner@umich.edu.
  • Lopez-Barcons L; Department of Internal Medicine, University of Michigan 1500 Medical Center Dr Ann Arbor MI 48109 USA.
  • Vandecan N; Department of Chemistry, University of Michigan 930 N. University Ave. Ann Arbor MI 48109 USA soellner@umich.edu.
  • Wu Z; Department of Internal Medicine, University of Michigan 1500 Medical Center Dr Ann Arbor MI 48109 USA.
  • Johnson TK; Department of Chemistry, University of Michigan 930 N. University Ave. Ann Arbor MI 48109 USA soellner@umich.edu.
  • Lachacz EJ; Department of Chemistry, University of Michigan 930 N. University Ave. Ann Arbor MI 48109 USA soellner@umich.edu.
  • Merajver SD; Department of Internal Medicine, University of Michigan 1500 Medical Center Dr Ann Arbor MI 48109 USA.
  • Soellner MB; Department of Chemistry, University of Michigan 930 N. University Ave. Ann Arbor MI 48109 USA soellner@umich.edu.
RSC Med Chem ; 13(1): 64-71, 2022 Jan 27.
Article em En | MEDLINE | ID: mdl-35224497
ABSTRACT
Scaffold hopping is a common strategy for generating kinase inhibitors that bind to the DFG-out inactive conformation. Small structural differences in inhibitor scaffolds can have significant effects on potency and selectivity across the kinome, however, these effects are often not studied in detail. Herein, we outline a design strategy to generate an array of DFG-out conformation inhibitors with three different hinge-binders and two DFG-pocket groups. We studied inhibitor selectivity across a large segment of the kinome and elucidated binding preferences that can be used in scaffold hopping campaigns. Using these analyses, we identified two selective inhibitors that display low nanomolar potency against Axl or wild-type and clinically relevant mutants of Abl.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article